Cardiac troponin I and NT-proBNP predict CV risk independent of FRS in psoriatic disease

Canada: Cardiac troponin I (cTnI), independent of traditional cardiovascular (CV) risk factors may reflect atherosclerosis risk in patients with the psoriatic disease (PsD), says a recent study published in the journal Arthritis and Rheumatology. 

Lihi Eder, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, and colleagues aimed to determine whether cardiac troponin I and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) in patients with the psoriatic disease is associated with carotid plaque burden and CV events development independent of the Framingham Risk Score (FRS).

For this purpose, the researchers measured carotid total plaque area (TPA) was measured in 358 participants at baseline among 1,000 patients with PsD. Automated clinical assays were used to measure cTnI and NT-proBNP. The association between carotid atherosclerosis and cardiac biomarkers was assessed by multivariable regression after adjusting for CV risk factors. Using measures of risk discrimination and reclassification, improvement in the prediction of CV events beyond the FRS.